Skip to content
Tenfell
Closed tender
Published 20 Feb 2017

(NU/1257) Clinical Trial Unit or Contracted Research Organisation to set up and manage Vision DMD Phase 2b and extension study

NEWCASTLE UNIVERSITY · United Kingdom

Key facts

Estimated value
£800,000
Closing date
22 Mar 2017
Contract starts
16 Apr 2017
Contract ends
30 Nov 2020
Procedure
Open procedure
Buyer type
Education

Description

This is an EU Open Tender. The scope of this contract relates specifically to the Phase 2b Randomized, Double-blind, Parallel Placebo- and Active-controlled Study to Assess the Efficacy and Safety of Vamorolone in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) and the extension study that will follow this. A registered Clinical Trial Unit (CTU) or Contracted Research Organisation (CRO) is required to set up and manage the clinical trial at sites in [UK/Australia/Israel/Sweden]. The CTU / CRO will be carrying out delegated duties on behalf of the sponsor, ReveraGen, but will be receiving payments for these duties from the Vision-DMD Horizon 2020 grant, coordinated by Newcastle University. This contract consists of 4 separate geographical Lots: Lot 1: UK Lot 2: Australia Lot 3: Israel Lot 4: Sweden

Categories (CPV)

Similar open tenders

About NEWCASTLE UNIVERSITY

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.